An economic analysis comparing health care resource use and cost of dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin versus gemcitabine and cisplatin as neoadjuvant therapy for muscle invasive bladder cancer.
Saved in:
| Title: | An economic analysis comparing health care resource use and cost of dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin versus gemcitabine and cisplatin as neoadjuvant therapy for muscle invasive bladder cancer. |
|---|---|
| Authors: | Montazeri, K.1,2 (AUTHOR), Dranitsaris, G.1,3 (AUTHOR), Thomas, JD.4 (AUTHOR), Curran, C.4 (AUTHOR), Preston, MA.5 (AUTHOR), Steele, GS.5 (AUTHOR), Kilbridge, KL.5 (AUTHOR), Mantia, C.6 (AUTHOR), Ravi, P.6 (AUTHOR), McGregor, BA.4 (AUTHOR), Mossanen, M.5 (AUTHOR), Sonpavde, G.1,4 (AUTHOR) gurup_sonpavde@dfci.harvard.edu, Thomas, J D4 (AUTHOR), Preston, M A7 (AUTHOR), Steele, G S7 (AUTHOR), Kilbridge, K L7 (AUTHOR), McGregor, B A4 (AUTHOR) |
| Source: | Urologic Oncology. Dec2021, Vol. 39 Issue 12, p834.e1-834.e7. 1p. |
| Database: | Academic Search Ultimate |
| ISSN: | 10781439 |
|---|---|
| DOI: | 10.1016/j.urolonc.2021.04.032 |
